---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-012154"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2023-04-13T23:59:59+00:00"
generated_at: "2026-06-17T02:39:36.935449+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Oncocyte cuts ~20% of workforce; expects $0.3M severance charges in Q2 2023

## Summary
- Reduction in force involving approximately 20% of employees, announced April 12, 2023.
- Estimated charges of about $0.3 million for severance and benefits in Q2 2023.
- Management says cuts align with kitted product strategy and extend cash runway into 2024.

## SEC filing metadata
- accession: 0001493152-23-012154
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2023-04-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315223012154/0001493152-23-012154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315223012154/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-012154
- JSON: https://secwatch.observer/filing/0001493152-23-012154.json
- Plain text: https://secwatch.observer/filing/0001493152-23-012154.txt

## Key facts
- Restructurings & Charges
  Insight Molecular Diagnostics Inc. announced a restructuring with charges of approximately $0.3 million related to employee severance and benefits costs affecting workforce (approximately 20% of its workforce).
  - Type: restructuring
  - Charge: approximately $0.3 million related to employee severance and benefits costs
  - Affected area: workforce
  - Headcount: approximately 20% of its workforce
  source text: On April 12, 2023, Oncocyte Corporation (the “Company” or “Oncocyte”) , announced a reduction in force involving approximately 20% of its workforce (the “Reduction”), which management believes will extend Oncocyte’s cash runway in 2024. In connection with the Reduction, Oncocyte estimates that it will incur charges of approximately $0.3 million related to employee severance and benefits costs in the second quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315223012154/0001493152-23-012154-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.